hsCRP (high-sensitivity C-reactive protein) measures systemic inflammation in the body. CRP is produced by the liver in response to inflammation; “high-sensitivity” testing detects low levels associated with chronic disease. hsCRP is independently associated with cardiovascular disease risk — elevated values predict heart attacks and strokes even when cholesterol levels are normal. Categories: under 1 mg/L low risk, 1-3 average, over 3 high, over 10 acute inflammation. Diabetes typically elevates hsCRP due to chronic low-grade inflammation — baseline 2-5 mg/L is common, higher than non-diabetic peers. Mechanisms: hyperglycemia stimulates inflammatory cytokines, adipose tissue (especially visceral fat) produces TNF-α and IL-6, insulin resistance is associated with chronic inflammation, often coexisting hypertension and obesity compound inflammation. Effective hsCRP reduction interventions: Mediterranean diet (strong evidence), weight loss (5-10% reduces significantly), regular exercise (both aerobic and resistance), glucose control (A1C reduction), smoking cessation (major reduction), reduce alcohol, statins (direct anti-inflammatory effect beyond cholesterol lowering), aspirin (modest), address dental/periodontal disease, treat sleep apnea, sleep adequacy, stress management, omega-3 fatty acids (modest), avoid processed foods/refined carbs/trans fats. The JUPITER trial demonstrated that statin therapy in adults with elevated hsCRP but normal LDL reduced cardiovascular events by 44%. Not all adults need routine hsCRP testing; most useful for refining risk assessment in intermediate cardiovascular risk.
hsCRP Risk Categories
| hsCRP Level | Cardiovascular Risk | Implication |
|---|---|---|
| under 1 mg/L | Low | Favorable; maintain healthy habits |
| 1-3 mg/L | Average | Standard prevention strategies |
| 3-10 mg/L | High | Address risk factors aggressively |
| over 10 mg/L | Very high or acute inflammation | Investigate cause; repeat after recovery if acute |
What Elevates hsCRP
- Chronic conditions: diabetes, obesity, hypertension, cardiovascular disease.
- Smoking — major contributor.
- Periodontal/gum disease.
- Autoimmune disease (lupus, rheumatoid arthritis).
- Infections — acute and chronic.
- Recent surgery or trauma — transient elevation.
- High alcohol intake.
- Sedentary lifestyle.
- Poor diet (processed foods, refined carbs, trans fats).
- Sleep deprivation.
- Chronic stress.
- Sleep apnea.
- Cancer (some types).
- Inflammatory bowel disease.
- Pregnancy (modest elevation normal).
Why hsCRP Matters Beyond Cholesterol
- JUPITER trial (Ridker 2008): statin therapy in adults with normal LDL but elevated hsCRP reduced cardiovascular events by 44%.
- hsCRP predicts cardiovascular events independently of LDL.
- Some adults have normal cholesterol but elevated cardiovascular risk — hsCRP identifies them.
- ACC/AHA risk calculator includes hsCRP as risk enhancer.
- Reclassifies adults from “low” to “moderate” risk in some cases.
- Useful for adults with intermediate risk to decide on statin therapy.
- Less useful for adults already at high risk (statin indicated regardless).
- Less useful for adults at very low risk (no intervention needed).
Lifestyle Interventions to Reduce hsCRP
- Mediterranean diet: strong evidence; multiple studies show 15-40% reduction.
- Weight loss: 5-10% body weight typically reduces hsCRP 25-50%.
- Regular exercise: 150 min/week reduces hsCRP modestly.
- Resistance training: additional benefit beyond aerobic.
- Smoking cessation: major reduction within months.
- Glucose control: A1C reduction correlates with hsCRP reduction.
- Sleep adequacy: 7-9 hours nightly.
- Stress management: meditation, yoga, therapy.
- Reduce processed foods: refined carbs, trans fats raise inflammation.
- Increase omega-3: fatty fish 2x weekly.
- Limit alcohol: moderate use only.
- Dental care: treat periodontal disease.
- Treat sleep apnea: if present.
Medications That Reduce hsCRP
- Statins: direct anti-inflammatory effect beyond cholesterol lowering.
- Aspirin: modest anti-inflammatory effect.
- Colchicine: anti-inflammatory; under study for cardiovascular prevention.
- SGLT2 inhibitors: modest hsCRP reduction.
- GLP-1 agonists: modest hsCRP reduction.
- Metformin: modest hsCRP reduction.
- Anti-IL-1β (canakinumab): dramatic hsCRP reduction; CANTOS trial.
- Methotrexate: not effective for cardiovascular prevention (CIRT trial).
- Niacin: minimal effect.
- Fibrates: modest reduction.
When to Test hsCRP
- Adults with intermediate cardiovascular risk to refine assessment.
- Adults considering statin therapy at intermediate risk.
- Adults with family history of cardiovascular disease.
- Some experts recommend in adults with diabetes for risk assessment.
- Not routinely in adults already on statin therapy.
- Not during acute illness or recent surgery (false elevation).
- If elevated initially, repeat in 2 weeks to confirm chronic vs acute.
- Use two measurements 2 weeks apart for accuracy.
Interpreting hsCRP in Diabetes
- Adults with diabetes typically have hsCRP 2-5 mg/L.
- This is higher than non-diabetic peers but reflects baseline diabetes inflammation.
- Reduction with interventions is the meaningful change.
- Track over time rather than single value.
- Consider in context of other risk factors.
- ADA doesn’t routinely recommend hsCRP testing but acknowledges value in selected adults.
- ACC/AHA risk calculator can use hsCRP as risk enhancer.
The Bottom Line
hsCRP (high-sensitivity C-reactive protein) measures systemic inflammation in the body. Produced by liver in response to inflammation; “high-sensitivity” testing detects low levels associated with chronic disease. hsCRP is independently associated with cardiovascular disease risk — elevated values predict heart attacks and strokes even when cholesterol levels are normal. Categories: under 1 mg/L low risk, 1-3 average, over 3 high, over 10 acute inflammation. Diabetes typically elevates hsCRP due to chronic low-grade inflammation — baseline 2-5 mg/L is common, higher than non-diabetic peers. Mechanisms include hyperglycemia stimulating inflammatory cytokines, adipose tissue (especially visceral fat) producing TNF-α and IL-6, insulin resistance, and often coexisting hypertension and obesity. The JUPITER trial demonstrated that statin therapy in adults with normal LDL but elevated hsCRP reduced cardiovascular events by 44% — establishing hsCRP as independent risk marker. ACC/AHA risk calculator includes hsCRP as risk enhancer; useful for adults at intermediate cardiovascular risk to refine decision on statin therapy. Effective hsCRP reduction interventions: Mediterranean diet (15-40% reduction), weight loss (5-10% body weight reduces hsCRP 25-50%), regular exercise (150 min/week, both aerobic and resistance), glucose control, smoking cessation (major reduction), sleep adequacy (7-9 hours), stress management, address periodontal disease, treat sleep apnea, omega-3 from fatty fish 2x weekly, limit alcohol, avoid processed foods/refined carbs/trans fats. Medications that reduce hsCRP: statins (direct anti-inflammatory beyond cholesterol lowering), aspirin (modest), SGLT2 inhibitors and GLP-1 agonists (modest), metformin (modest). Not routinely recommended for all adults; most useful for intermediate cardiovascular risk to refine statin decision. For adults with type 2 diabetes, baseline elevation is expected; reduction with comprehensive lifestyle changes correlates with reduced cardiovascular risk. See our broader diabetes heart attack risk guide for context.
